Intrinsically disordered proteins are potential drug targets

Current Opinion in Chemical Biology

Volumn 14, Issue 4, 2010, Pages 481-488

  Metallo, Steven J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BCR ABL PROTEIN; BINDING PROTEIN; HYBRID PROTEIN; INTRINSICALLY DISORDERED PROTEIN; MAX PROTEIN; MYC PROTEIN; ONCOPROTEIN; PACLITAXEL; PEPTIDE; PROTEIN EWS FLI1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; COMPLEX FORMATION; DIMERIZATION; DNA BINDING; DRUG PROTEIN BINDING; FEASIBILITY STUDY; FUNGAL GENE; GENE OVEREXPRESSION; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS;

DRUG DELIVERY SYSTEMS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EUKARYOTA;

EID: 77955327536     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2010.06.169     Document Type: Review

References (65)

1. Imming P., Sinning C., Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006, 5:821-834.
2. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
3. Yin H., Hamilton A.D. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed 2005, 44:4130-4163.
4. Clackson T., Wells J.A. A hot-spot of binding-energy in a hormone-receptor interface. Science 1995, 267:383-386.
5. Dunker A.K., Silman I., Uversky V.N., Sussman J.L. Function and structure of inherently disordered proteins. Curr Opin Struct Biol 2008, 18:756-764.
6. Eliezer D. Biophysical characterization of intrinsically disordered proteins. Curr Opin Struct Biol 2009, 19:23-30.
7. Uversky V.N., Dunker A.K. Understanding protein non-folding. Biochim Biophys Acta 2010, 1804:1231-1264.
8. Mittag T., Kay L.E., Forman-Kay J.D. Protein dynamics and conformational disorder in molecular recognition. J Mol Recognit 2010, 23:105-116.
9. Tompa P., Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci 2008, 33:2-8.
10. Uversky V.N., Oldfield C.J., Dunker A.K. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys 2008, 37:215-246.
11. Wright P.E., Dyson H.J. Linking folding and binding. Curr Opin Struct Biol 2009, 19:31-38.
12. Dyson H.J., Wright P.E. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005, 6:197-208.
13. Vavouri T., Semple J.I., Garcia-Verdugo R., Lehner B. Intrinsic protein disorder and interaction promiscuity are widely associated with dosage sensitivity. Cell 2009, 138:198-208.
14. Gsponer J., Futschik M.E., Teichmann S.A., Babu M.M. Tight regulation of unstructured proteins: from transcript synthesis to protein degradation. Science 2008, 322:1365-1368.
15. He B., Wang K.J., Liu Y.L., Xue B., Uversky V.N., Dunker A.K. Predicting intrinsic disorder in proteins: an overview. Cell Res 2009, 19:929-949.
16. Vacic V., Oldfield C.J., Mohan A., Radivojac P., Cortese M.S., Uversky V.N., Dunker A.K. Characterization of molecular recognition features, MoRFs, and their binding partners. J Proteome Res 2007, 6:2351-2366.
17. Cheng Y.G., Oldfield C.J., Meng J.W., Romero P., Uversky V.N., Dunker A.K. Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry 2007, 46:13468-13477.
18. Meszaros B., Simon I., Dosztanyi Z. Prediction of protein binding regions in disordered proteins. PLoS Comput Biol 2009, 5:e1000376.
19. Adhikary S., Eilers M. Transcriptional regulation and transformation by MYC proteins. Nat Rev Mol Cell Biol 2005, 6:635-645.
20. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., Golub T.R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000, 97:3260-3265.
21. Dang C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999, 19:1-11.
22. Blackwood E.M., Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991, 251:1211-1217.
23. Nair S.K., Burley S.K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003, 112:193-205.
24. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
25. Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., Karnezis A.N., Swigart L.B., Nasi S., Evan G.I. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
26. Ponzielli R., Katz S., Barsyte-Lovejoy D., Penn L.Z. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005, 41:2485-2501.
27. Prochownik E.V. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 2004, 4:289-302.
28. Vita M., Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Sem Cancer Biol 2006, 16:318-330.
29. Follis A.V., Hammoudeh D.I., Wang H.B., Prochownik E.V., Metallo S.J. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol 2008, 15:1149-1155.
30. Hammoudeh D.I., Follis A.V., Prochownik E.V., Metallo S.J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc 2009, 131:7390-7401.
31. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 2002, 99:3830-3835.
32. Shi J., Stover J.S., Whitby L.R., Vogt P.K., Boger D.L. Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett 2009, 19:6038-6041.
33. Yin X., Giap C., Lazo J.S., Prochownik E.V. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003, 22:6151-6159.
34. Wang H., Hammoudeh D.I., Follis A.V., Reese B.E., Lazo J.S., Metallo S.J., Prochownik E.V. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007, 6:2399-2408.
35. Mustata G., Follis A.V., Hammoudeh D.I., Metallo S.J., Wang H.B., Prochownik E.V., Lazo J.S., Bahar I. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem 2009, 52:1247-1250.
36. Crespo A., Fernandez A. Induced disorder in protein-ligand complexes as a drug-design strategy. Mol Pharmacol 2008, 5:430-437.
37. Lee G.M., Craik C.S. Trapping moving targets with small molecules. Science 2009, 324:213-215.
38. Hilser V.J., Thompson E.B. Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins. Proc Natl Acad Sci U S A 2007, 104:8311-8315.
39. Xu Y., Shi J., Yamamoto N., Moss J.A., Vogt P.K., Janda K.D. A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem 2006, 14:2660-2673.
40. Kiessling A., Sperl B., Hollis A., Eick D., Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 2006, 13:745-751.
41. Kiessling A., Wiesinger R., Sperl B., Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]-pyrimidine. ChemMedChem 2007, 2:627-630.
42. Grote D., Hanel F., Dahse H.M., Seifert K. Capnellenes from the soft coral Dendronephthya rubeola. Chem Biodivers 2008, 5:1683-1693.
43. Jiang H., Bower K.E., Beuscher A.E., Zhou B., Bobkov A.A., Olson A.J., Vogt P.K. Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. Mol Pharmacol 2009, 76:491-502.
44. Mo H., Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci U S A 2006, 103:6344-6349.
45. Mo H., Vita M., Crespin M., Henriksson M. Myc overexpression enhances apoptosis induced by small molecules. Cell Cycle 2006, 5:2191-2194.
46. Cozzini P., Kellogg G.E., Spyrakis F., Abraham D.J., Costantino G., Emerson A., Fanelli F., Gohlke H., Kuhn L.A., Morris G.M., et al. Target flexibility: an emerging consideration in drug discovery and design. J Med Chem 2008, 51:6237-6255.
47. Kukar T.L., Ladd T.B., Bann M.A., Fraering P.C., Narlawar R., Maharvi G.M., Healy B., Chapman R., Welzel A.T., Price R.W., et al. Substrate-targeting gamma-secretase modulators. Nature 2008, 453:925-929.
48. Tompa P. Structural disorder in amyloid fibrils: its implication in dynamic interactions of proteins. FEBS J 2009, 276:5406-5415.
49. Uversky V.N. Intrinsic disorder in proteins associated with neurodegenerative diseases. Front Biosci 2009, 14:5188-5238.
50. Kodadek T. Inhibition of proteolysis and other posttranslational modifications with substrate-targeted inhibitors. Biopolymers 2002, 66:134-140.
51. Weiss S.T., McIntyre N.R., McLaughlin M.L., Merkler D.J. The development of molecular clamps as drugs. Drug Discov Today 2006, 11:819-824.
52. Xie H.B., Vucetic S., Iakoucheva L.M., Oldfield C.J., Dunker A.K., Obradovic Z., Uversky V.N. Functional anthology of intrinsic disorder. 3. Ligands, post-translational modifications, and diseases associated with intrinsically disordered proteins. J Proteome Res 2007, 6:1917-1932.
53. Uren A., Tcherkasskaya O., Toretsky J.A. Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry 2004, 43:13579-13589.
54. Erkizan H.V., Kong Y.L., Merchant M., Schlottmann S., Barber-Rotenberg J.S., Yuan L.S., Abaan O.D., Chou T.H., Dakshanamurthy S., Brown M.L., et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009, 15:750-758.
55. Rodi D.J., Agoston G.E., Manon R., Lapcevich R., Green S.J., Makowski L. Identification of small molecule binding sites within proteins using phage display technology. Comb Chem High Throughput Screen 2001, 4:553-572.
56. Rodi D.J., Janes R.W., Sanganee H.J., Holton R.A., Wallace B.A., Makowski L. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 1999, 285:197-203.
57. Aoki S., Morohashi K., Sunoki T., Kuramochi K., Kobayashi S., Sugawara F. Screening of paclitaxel-binding molecules from a library of random peptides displayed on t7 phage particles using paclitaxel-photoimmobilized resin. Bioconjugate Chem 2007, 18:1981-1986.
58. Morohashi K., Yoshino A., Yoshimori A., Saito S., Tanuma S., Sakaguchi K., Sugawara F. Identification of a drug target motif: an anti-tumor drug NK109 interacts with a PNxxxxP. Biochem Pharmacol 2005, 70:37-46.
59. Nishiyama K., Takakusagi Y., Kusayanagi T., Matsumoto Y., Habu S., Kuramochi K., Sugawara F., Sakaguchi K., Takahashi H., Natsugari H., et al. Identification of trimannoside-recognizing peptide sequences from a T7 phage display screen using a QCM device. Bioorg Med Chem 2009, 17:195-202.
60. Takakusagi Y., Kobayashi S., Sugawara F. Camptothecin binds to a synthetic peptide identified by a T7 phage display screen. Bioorg Med Chem Lett 2005, 15:4850-4853.
61. Masuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T., Hisanaga S., Goedert M., Hasegawa M. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 2006, 45:6085-6094.
62. Lendel C., Bolognesi B., Wahlstrom A., Dobson C.M., Graslund A. Detergent-like interaction of Congo red with the amyloid beta peptide. Biochemistry 2010, 49:1358-1360.
63. Feng B.Y., Toyama B.H., Wille H., Colby D.W., Collins S.R., May B.C.H., Prusiner S.B., Weissman J., Shoichet B.K. Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol 2008, 4:197-199.
64. Fuxreiter M., Tompa P., Simon I., Uversky V.N., Hansen J.C., Asturias F.J. Malleable machines take shape in eukaryotic transcriptional regulation. Nat Chem Biol 2008, 4:728-737.
65. Mestres J., Gregori-Puigjane E., Valverde S., Sole R.V. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol BioSyst 2009, 5:1051-1057.